Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice
about
Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Recent advance in antigen-specific immunotherapy for acute myeloid leukemiaAdoptive T-cell therapy for LeukemiaCpG oligodeoxynucleotides enhance the efficacy of adoptive cell transfer using tumor infiltrating lymphocytes by modifying the Th1 polarization and local infiltration of Th17 cellsAdoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.Generation of diffuse large B cell lymphoma-associated antigen-specific Vα6/Vβ13+T cells by TCR gene transfer.Comparison of lentiviral and sleeping beauty mediated αβ T cell receptor gene transfer.Adiponectin receptor signaling on dendritic cells blunts antitumor immunityAdoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015.Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target MalignanciesAugmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies.Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells.Application of adoptive T-cell therapy using tumor antigen-specific T-cell receptor gene transfer for the treatment of human leukemia.Cellular immunotherapy for high-grade glioma.Requisite considerations for successful adoptive immunotherapy with engineered T-lymphocytes using tumor antigen-specific T-cell receptor gene transfer.Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies.Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia.Clinical peptide vaccination trials for leukemia patients.Genetic engineering of T cells for the immunotherapy of haematological malignancies.Cellular immunotherapy for malignant gliomas.In vitro generation of mature, naive antigen-specific CD8(+) T cells with a single T-cell receptor by agonist selection.Dominant responses with conservation of T-cell receptor usage in the CD8+ T-cell recognition of a cancer testis antigen peptide presented through HLA-Cw7 in patients with multiple myeloma.Nilotinib: evaluation and analysis of its role in chronic myeloid leukemia.High-Throughput Analysis of the T Cell Receptor Beta Chain Repertoire in PBMCs from Chronic Hepatitis B Patients with HBeAg SeroconversionTCR-engineered T cells: a model of inducible TCR expression to dissect the interrelationship between two TCRsAdoptive Immunotherapy after Allogeneic Hematopoietic Progenitor Cell Transplantation: New Perspectives for Transfusion MedicineT-cell receptor gene transfer for the treatment of leukemia and other tumors.Human MHC Class I-restricted high avidity CD4+ T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo.The progress and current status of immunotherapy in acute myeloid leukemia.WT1 Mutation in Childhood Cancer.
P2860
Q26770391-4E87A5A9-5420-4F18-AF62-8E080D790552Q27005765-1D4D1354-37E8-4E0F-A0B8-A1D9197A86A5Q27006934-809D7F08-3BBF-47DB-9F24-45558B26AD55Q34235739-2B13D13F-B084-40FA-9D0A-C08B0A8C43F9Q34279672-EB045723-FF2D-4093-8007-467659B31EF3Q34506910-07F176BD-981D-43F2-BCC6-E8C04F05646EQ34808631-488FECCD-59BE-476C-A3CC-8D90BE76DA4EQ35041976-19659608-5790-4A75-B535-71B8CEE03525Q35641721-BF79FD0C-D1B5-447D-AC49-28283EF8E5E2Q35711576-AB0486EE-EF4A-4D57-A575-8F3855C69D77Q36558375-4C06CB28-722B-4085-829A-9E62084A49FFQ36662079-AA17FD1D-FBE7-4A9A-A12A-48338C2CDFA3Q37107843-FE412135-B797-4820-8871-587D374E68D8Q37242561-795CD902-3E8A-4C98-AE08-33A9A4884473Q37747066-FBF7F02F-D9DA-4276-945B-BE2D07663E68Q37851972-85596531-B0B5-43F1-B23F-F17352EA5C49Q37854072-EBEC2BFF-B23F-4EBB-B817-019B0EC48941Q37863518-D9474F34-F72B-43D0-ADE8-FA7D0C2E317CQ37868974-C7529973-E4B0-46EB-B0A3-96BC5669098EQ37892584-546969C9-676C-48F3-A5C5-D2B547C963D3Q37965815-3C272C24-B555-4C95-B708-E9FB111CD9B0Q38902169-0BFC7B92-5306-4C9D-B988-7E6E06FE3BACQ39087734-FAEA091A-1F24-4F6C-9C9F-BE6F8E995751Q39501485-B8652A09-B617-4365-99E7-B8706AB30BF6Q39779762-3AC7CB1B-073D-4CC2-893F-1D3DF71E39B2Q40486931-6C493F78-7C97-406D-9B48-A710BD9F9444Q41837100-4605B431-84C6-443C-885A-AD6AB84D1D5CQ42783189-7634C7C7-9E54-4C53-86D7-8E2EBC5D389FQ42938317-3CC3A89E-0473-4404-B84D-D2C026DE172CQ43238571-D6D82B7A-AC32-4E72-B664-909FAED35239Q47590707-512C8BE0-092F-417E-8A32-CC35C5726FC0Q50498738-851146FE-36AC-4796-8849-014DAC3E77F8
P2860
Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Development of a Wilms' tumor ...... ukemia blasts in NOD/SCID mice
@ast
Development of a Wilms' tumor ...... ukemia blasts in NOD/SCID mice
@en
Development of a Wilms' tumor ...... kemia blasts in NOD/SCID mice.
@nl
type
label
Development of a Wilms' tumor ...... ukemia blasts in NOD/SCID mice
@ast
Development of a Wilms' tumor ...... ukemia blasts in NOD/SCID mice
@en
Development of a Wilms' tumor ...... kemia blasts in NOD/SCID mice.
@nl
prefLabel
Development of a Wilms' tumor ...... ukemia blasts in NOD/SCID mice
@ast
Development of a Wilms' tumor ...... ukemia blasts in NOD/SCID mice
@en
Development of a Wilms' tumor ...... kemia blasts in NOD/SCID mice.
@nl
P2093
P2860
P1433
P1476
Development of a Wilms' tumor ...... ukemia blasts in NOD/SCID mice
@en
P2093
Daniel P Hart
Emma Morris
Hans J Stauss
Liquan Gao
Ralf-Holger Voss
Roopinder Gillmore
Shao-An Xue
Sharyn Thomas
P2860
P304
P356
10.3324/HAEMATOL.2009.006486
P50
P577
2009-08-13T00:00:00Z